-
Two recent reports provide information regarding durability of complete remission for those treated for acute myeloid leukemia. The rapidity with which blasts are cleared from the peripheral blood turns out to be an excellent predictor of relapse free survival. For those who remain in complete remission at 3 years, cytogenetic features and patient age remain predictors of relapse.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
-
-
-
Neither antibiotics nor nasal steroids nor the combination of the two reduces the duration of acute sinusitis symptoms compared with placebo.
-
IV bisphosphonate treatment is associated with an increased risk of inflammation in the bones of the jaw and face.
-
Although pancreatic cancer growth is considered rapid, early recognition of resectable disease remains the best chance for long-term survival. It is possible that an early sign of evolving pancreatic neoplasm is glucose intolerance. In a series of 30 pancreatic cancer patients evaluated at the Mayo Clinic, CT scans obtained 6 months or more before the diagnosis revealed potentially resectable lesions in some, and this was notably true for those who had CT scans and new-onset diabetes several months before the diagnosis of pancreatic cancer. Thus, physicians evaluating adults with newly diagnosed diabetes should consider the possibility that the glucose intolerance is an accompaniment of early pancreatic neoplasia.
-
Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
-
Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
